Sanofi
SABS icon

Sanofi’s SAB Biotherapeutics SABS Stock Holding History

Sanofi’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.97M Buy
+2,198,500
New +$8M 1.11% 15

Other funds holding SABS

HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
First PREMIER Bank
First PREMIER Bank Sioux Falls, South Dakota $621M AUM 13.03% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Plante Moran Financial Advisors
Plante Moran Financial Advisors Southfield, Michigan $2.2B AUM 13.29% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sanofi's SABS Position: Q3 2026 in Review

Sanofi opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 2,198,500 shares worth $6.97M. The stake represents 1.11% of the portfolio and ranks #15 among its holdings.

18 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Sanofi held 2,198,500 shares of SAB Biotherapeutics worth $6.97M as of Q3 2026.
  • SAB Biotherapeutics was a new Sanofi position in Q3 2026.
  • SAB Biotherapeutics made up 1.11% of Sanofi's portfolio in Q3 2026, its #15 holding.
  • 18 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Sanofi's 13F filing for Q3 2026, filed 5 Nov 2026.